The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis

被引:507
作者
Gelperina, S
Kisich, K
Iseman, MD
Heifets, L
机构
[1] Natl Jewish Med & Res Ctr, Denver, CO USA
[2] Res Ctr Mol Diagnost & Therapy, Moscow, Russia
关键词
antituberculosis drugs; nanoparticles; tuberculosis therapy;
D O I
10.1164/rccm.200504-613PP
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Nanoparticle-based drug delivery systems have considerable potential for treatment of tuberculosis (TB). The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation. Nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix. These properties of nanoparticles enable improvement of drug bioavailability and reduction of the dosing frequency, and may resolve the problem of nonadherence to prescribed therapy, which is one of the major obstacles in the control of TB epidemics. This article highlights some of the issues of nano-technology relevant to the anti-TB drugs.
引用
收藏
页码:1487 / 1490
页数:4
相关论文
共 32 条
[1]  
Ain Q, 2002, INT J PHARM, V239, P37, DOI 10.1016/S0378-5173(02)00034-0
[2]   Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages [J].
Anisimova, Y. V. ;
Gelperina, S. I. ;
Peloquin, C. A. ;
Heifets, L. B. .
JOURNAL OF NANOPARTICLE RESEARCH, 2000, 2 (02) :165-171
[3]   PLGA nanoparticles in drug delivery: The state of the art [J].
Bala, I ;
Hariharan, S ;
Kumar, MNVR .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2004, 21 (05) :387-422
[4]   Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages [J].
Barrow, ELW ;
Winchester, GA ;
Staas, JK ;
Quenelle, DC ;
Barrow, WW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2682-2689
[5]  
Bummer PM, 2004, CRIT REV THER DRUG, V21, P1
[6]   Nanocapsule technology: A review [J].
Couvreur, P ;
Barratt, G ;
Fattal, E ;
Legrand, P ;
Vauthier, C .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2002, 19 (02) :99-134
[7]   Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles [J].
Dutt, M ;
Khuller, GK .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (06) :829-835
[8]   Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity [J].
Fawaz, F ;
Bonini, F ;
Maugein, J ;
Lagueny, AM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 168 (02) :255-259
[9]   Issues in oral nanoparticle drug carrier uptake and targeting [J].
Florence, AT .
JOURNAL OF DRUG TARGETING, 2004, 12 (02) :65-70
[10]   Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas [J].
Florence, AT ;
Hussain, N .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 50 :S69-S89